Voyager Therapeutics
VYGR
78 hedge funds and large institutions have $142M invested in Voyager Therapeutics in 2022 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 16 increasing their positions, 27 reducing their positions, and 14 closing their positions.
616% more call options, than puts
Call options by funds: $4.43M | Put options by funds: $619K
57% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 14
11% more funds holding
Funds holding: 70 → 78 (+8)
3.66% more ownership
Funds ownership: 58.95% → 62.61% (+3.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
17% less capital invested
Capital invested by funds: $171M → $142M (-$29M)
41% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$8.08M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$5.29M |
| 3 |
Millennium Management
New York
|
+$4.37M |
| 4 |
AC
Armistice Capital
New York
|
+$3.81M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$888K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$7.09M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
-$2.59M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$2.33M |
| 4 |
EGI
EAM Global Investors
Solana Beach,
California
|
-$1.71M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$1.02M |
VYGR Hedge Fund Activity: Q2 2022 in Review
78 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Voyager Therapeutics (VYGR) for Q2 2022, worth a combined $142M — down 17% from $171M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new VYGR positions and 14 closed out — a net gain of 8 holders — while 16 added to existing stakes and 27 trimmed.
The largest buyer was EcoR1 Capital, adding an estimated $8.08M. The largest seller was BVF Inc, cutting an estimated $7.09M.
- 78 institutional investors held Voyager Therapeutics (VYGR) as of Q2 2022, up from 70 in Q1 2022.
- Funds reported $142M of Voyager Therapeutics stock for Q2 2022, down 17% quarter-over-quarter.
- 22 funds opened new Voyager Therapeutics positions in Q2 2022 and 14 closed out, a net change of +8 holders.
- The largest Voyager Therapeutics buyer in Q2 2022 was EcoR1 Capital, an estimated $8.08M added.
- The largest Voyager Therapeutics seller in Q2 2022 was BVF Inc, an estimated $7.09M sold.
Based on aggregated 13F filings for Q2 2022.